Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis

Authors

• Marina Rodrigues Lima Faculty of Medicine, University Center UNINTA, Sobral, Ceará, Brazil.
• Luis Arthur Brasil Gadelha Farias Faculty of Medicine, Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil
• Maycon Fellipe da Ponte Internal Medicine Department, Hospital Regional Norte (HRN), Sobral, Ceará, Brazil.
• Luís Edmundo Teixeira de Arruda Furtado Internal Medicine Department, Hospital Regional Norte (HRN), Sobral, Ceará, Brazil.

luisarthurbrasilk@hotmail.com

Keywords

Abstract

Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequently developed self-limited cytomegalovirus disease.
Cytomegalovirus infection has been reported during treatment with natalizumab, and in this study, we use new techniques to analyze the possible association of cytomegalovirus infection with natalizumab.